Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
Delivery costs do not apply or are included.
Ask a question about this product
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting epithelial growth factor receptor (EGF-R) in comparison with originator anti-EGF-R antibodies to treat solid tumors as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
Table of Contents
1. Sales of Anti-EGF-R Antibodies
2. Originator Anti-EGF-R Antibodies
Erbitux Approved Indications & Pipeline
Vectibix Approved Indications & Pipeline
Nimotuzumab Approved Indications & Pipeline
Portrazza Approved Indications & Pipeline
3. Biosuperior Anti-EGF-R Antibodies
3rd Generation Anti-EGF-R Antibodies
Bispecific Anti-EGF-R Antibodies
Anti-EGF-R Antibody Drug Conjugates
4. Biosimilar Anti-EGF-R Antibodies
Erbitux Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets
5. Corporate Anti-EGF-R Biosimilar & Biosuperior Antibody Pipelines